Lupin Divests US Women’s Health Biz to Evofem for $84 Mn

Under the terms of the agreement, Lupin stands to receive up to $84 million, contingent upon achieving specified future milestones.

Global pharmaceutical company Lupin has sold its US commercial women’s health specialty business to Evofem Biosciences, a US biopharmaceutical company that focuses solely on women’s health.

Under the terms of the agreement, Lupin stands to receive up to $84 million, contingent upon achieving specified future milestones.

This strategic move allows Evofem to expand its portfolio and strengthen its position in women’s health. Further, with this acquisition, Evofem gains Lupin’s existing products, market presence, and expertise.

‘’We can now fully use our commercial infrastructure, capitalise on our strong physician contacts, and relaunch an asset with significant growth potential’, stated Saundra Pelletier, CEO of Evofem.

This strategic divestiture includes the transfer of Lupin’s primary US product, SOLOSEC (secnidazole) 2g oral granules, an FDA-approved, single-dose antibiotic used for the treatment of bacterial vaginosis (BV) and trichomoniasis.

Per pharmaceutical giant Lupin, this divestiture seeks to focus on optimizing its portfolio to better align with strategic priorities despite government-imposed pricing limitations on anti-TB medications.

Expressing thoughts, Dr Fabrice Egros, President of Global Corporate Development at Lupin, said. ‘’We are very pleased to divest our US commercial women’s health specialty business, including SOLOSEC, to Evofem. This disposal is another step towards aligning our US specialist company with our strategy plan to grow our specialty business in therapeutic areas with synergistic building blocks. These include respiratory and neurological disorders.’’

This sale is seen as a step towards refining Lupin's business focus, allowing it to direct resources and efforts towards more synergistic therapeutic areas and enhance its specialty business capabilities.

Lupin’s US Commercial Women’s Health Specialty Business was established in 2003 with the reintroduction of Suprax (Cefixime) oral suspension.

While Evofem Biosciences, on the other hand, was founded in 2009 by Saundra Pelletier. It aims to empower women by providing innovative products that give them more control over their sexual and reproductive health.

Lupin’s Noteworthy Initiatives

Last month, Lupin appointed Abdelaziz Toumi as the CEO of its newly established subsidiary, Lupin Manufacturing Solutions (LMS).

In a related development, Lupin Digital Health, a prominent player in the digital health sector, announced a significant achievement for its Lyfe platform. The platform secured approval as a Class C Medical Device from the Central Drugs Standard Control Organization (CDSCO).

Last year, Lupin introduced several patient engagement programs in the digital health space. 'Humrahi, a patient support program, focuses on helping patients manage diabetes, while Jeet promotes heart health by offering cost-effective medical solutions, disease counseling, medication reminders, and lifestyle guidance.